Database : MEDLINE
Search on : Mast-Cell and Sarcoma [Words]
References found : 2250 [refine]
Displaying: 1 .. 10   in format [Detailed]

page 1 of 225 go to page                         

  1 / 2250 MEDLINE  
              next record last record
select
to print
Photocopy
Full text

[PMID]: 28520972
[Au] Autor:Astle JM; Rose MG; Racke FK; Tormey CA; Siddon AJ
[Ad] Address:Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA.
[Ti] Title:R634W KIT Mutation in an Adult With Systemic Mastocytosis.
[So] Source:Lab Med;48(3):253-257, 2017 Aug 01.
[Is] ISSN:1943-7730
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:Mastocytosis is a clonal neoplasm with the potential to affect various organs within the body. It can range in clinical severity from benign to extremely aggressive. Mastocytosis can be separated into cutaneous, systemic, and leukemic forms, as well as mast-cell sarcoma and extracutaneous mastocytoma. It is most often an acquired condition but can be inherited; the most commonly identified genetic aberrations leading to mastocytosis are activating mutations involving codon 816 of the KIT gene. Herein, we present the case of a 30-year-old Caucasian man with systemic mastocytosis discovered to have a p.Arg634Trp mutation involving KIT. To our knowledge, this mutation has previously only been identified in children with familial urticarial pigmentosa. Ours is the the first case report in the literature of an adult with systemic mastocytosis likely due to a p.Arg634Trp KIT mutation.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1705
[Cu] Class update date: 170921
[Lr] Last revision date:170921
[St] Status:In-Process
[do] DOI:10.1093/labmed/lmx026

  2 / 2250 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 28412213
[Au] Autor:Wang RC; Ward D; Dunn P; Chang CC
[Ad] Address:Department of Pathology and Laboratory Medicine, Florida Hospital, Orlando, FL, 32803; Department of Pathology and Laboratory Medicine, Taichung Veteran General Hospital, Taichung, Taiwan, 40705.
[Ti] Title:Acute mast cell leukemia associated with t(4;5)(q21;q33).
[So] Source:Hum Pathol;67:198-204, 2017 Sep.
[Is] ISSN:1532-8392
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:To the best of our knowledge, this manuscript describes clinical and pathologic findings of the first case of acute mast cell leukemia harboring t(4;5)(q21;q33), compatible with fusion of the PDGFRB gene to a rare partner, PRKG2. Translocation involving the PDGFRB gene is confirmed by fluorescence in situ hybridization study. This case presented a relatively fulminant clinical course with acute mast cell leukemia and "C" findings (cytopenia, hepatosplenomegaly, and weight loss), mast cell sarcoma, and severe basophilia. Despite aggressive presentation initially, the patient responded well to tyrosine kinase inhibitor treatment and is currently in complete remission 33 months after diagnosis. This case significantly extends the disease spectrum associated with PRKG2/PDGFRB fusion gene. Recognizing the whole spectrum of diseases associated with this fusion is critical because tyrosine kinase inhibitor treatment has been exceedingly effective in these patients.
[Mh] MeSH terms primary: Biomarkers, Tumor/genetics
Chromosomes, Human, Pair 4
Chromosomes, Human, Pair 5
Leukemia, Mast-Cell/genetics
Translocation, Genetic
[Mh] MeSH terms secundary: Acute Disease
Antineoplastic Agents/therapeutic use
Biopsy
Cyclic GMP-Dependent Protein Kinase Type II/genetics
Gene Fusion
Genetic Predisposition to Disease
Humans
Imatinib Mesylate/therapeutic use
Immunohistochemistry
Leukemia, Mast-Cell/drug therapy
Leukemia, Mast-Cell/enzymology
Leukemia, Mast-Cell/pathology
Male
Middle Aged
Molecular Diagnostic Techniques
Molecular Targeted Therapy
Phenotype
Protein Kinase Inhibitors/therapeutic use
Receptor, Platelet-Derived Growth Factor beta/genetics
Remission Induction
Time Factors
Treatment Outcome
[Pt] Publication type:CASE REPORTS; JOURNAL ARTICLE
[Nm] Name of substance:0 (Antineoplastic Agents); 0 (Biomarkers, Tumor); 0 (Protein Kinase Inhibitors); 8A1O1M485B (Imatinib Mesylate); EC 2.7.10.1 (PDGFRB protein, human); EC 2.7.10.1 (Receptor, Platelet-Derived Growth Factor beta); EC 2.7.11.12 (Cyclic GMP-Dependent Protein Kinase Type II); EC 2.7.11.12 (PRKG2 protein, human)
[Em] Entry month:1710
[Cu] Class update date: 171016
[Lr] Last revision date:171016
[Js] Journal subset:IM
[Da] Date of entry for processing:170417
[St] Status:MEDLINE

  3 / 2250 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 27889201
[Au] Autor:Giuliano A; Dos Santos Horta R; Constantino-Casas F; Hoather T; Dobson J
[Ad] Address:University of Cambridge, Department of Veterinary Medicine, Madingley Road, Cambridge, UK. Electronic address: ag847@cam.ac.uk.
[Ti] Title:Expression of Fibroblast Activating Protein and Correlation with Histological Grade, Mitotic Index and Ki67 Expression in Canine Mast Cell Tumours.
[So] Source:J Comp Pathol;156(1):14-20, 2017 Jan.
[Is] ISSN:1532-3129
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:Fibroblast activating protein (FAP) is a membrane serine protease expressed by activated fibroblasts, particularly tumour associated fibroblasts (TAFs). FAP expression has not been reported in canine mast cell tumours (MCTs). The objective of this study was to evaluate the expression of FAP in TAFs and its correlation with histological grade, mitotic index and Ki67 expression in canine MCTs. FAP expression was evaluated by immunohistochemistry (IHC) in 30 canine MCTs. Twenty-eight (90%) of the MCTs expressed FAP in the stroma, 16 cases showed low to intermediate FAP score and 14 cases had a high FAP score. FAP was correlated positively with both Patnaik (P = 0.007) and Kiupel (P = 0.008) grading systems, mitotic index (P = 0.0008) and Ki67 expression (P = 0.009). High stromal FAP expression could be a potential negative prognostic factor in canine MCTs.
[Mh] MeSH terms primary: Dog Diseases/pathology
Fibroblasts/pathology
Gelatinases/biosynthesis
Mast-Cell Sarcoma/veterinary
Mastocytoma/veterinary
Membrane Proteins/biosynthesis
Serine Endopeptidases/biosynthesis
[Mh] MeSH terms secundary: Animals
Dog Diseases/metabolism
Dogs
Immunohistochemistry
Ki-67 Antigen/biosynthesis
Mitotic Index
Neoplasm Grading
[Pt] Publication type:JOURNAL ARTICLE
[Nm] Name of substance:0 (Ki-67 Antigen); 0 (Membrane Proteins); EC 3.4.21.- (Serine Endopeptidases); EC 3.4.21.- (fibroblast activation protein alpha); EC 3.4.24.- (Gelatinases)
[Em] Entry month:1705
[Cu] Class update date: 170525
[Lr] Last revision date:170525
[Js] Journal subset:IM
[Da] Date of entry for processing:161128
[St] Status:MEDLINE

  4 / 2250 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 26109175
[Au] Autor:Moretti P; Giordano A; Stefanello D; Ferrari R; Castellano S; Paltrinieri S
[Ad] Address:Department of Veterinary Sciences and Public Health, University of Milan, Milan, Italy.
[Ti] Title:Nucleated erythrocytes in blood smears of dogs undergoing chemotherapy.
[So] Source:Vet Comp Oncol;15(1):215-225, 2017 Mar.
[Is] ISSN:1476-5829
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:The frequency of normoblastemia in dogs receiving chemotherapy is unknown. To provide this information, we calculated the percentage and number of nucleated erythrocytes (nRBCs) in blood of dogs treated for lymphoma (n = 284), mast cell tumour (n = 40) or carcinoma (n = 46). Relative normoblastemia (>1 or >5%) and absolute normoblastemia (>0.1 or >0.4 × 10 µL ) were found after administration of vincristine (49.3, 20.5, 42.5, 19.2%, respectively), carboplatin (37.0, 2.2, 34.8, 13.0%), cyclophosphamide (30.8, 7.7, 23.1, 7.7%), doxorubicin (25.0, 8.3, 21.7, 6.7%), vinblastine and prednisone (25.0; 5.0; 22.5; 7.5%). Absolute normoblastemia was very severe (>1.0 × 10 nRBC µL ) after administration of vincristine (9.6%), doxorubicin (3.3%), vinblastine and prednisone (2.5%). Absolute normoblastemia negatively correlated with RBC counts (P < 0.001) and positively (P < 0.001) with reticulocyte and WBC counts, but correlation coefficients were low (-0.19, 0.37, 0.15). Vincristine, doxorubicin or vinblastine and prednisone may induce severe normoblastemia. This may increase WBC counts and mask neutropenia associated with chemotherapy.
[Mh] MeSH terms primary: Antineoplastic Agents/adverse effects
Carcinoma/veterinary
Dog Diseases/blood
Erythroblasts/drug effects
Lymphoma/veterinary
Mastocytosis/veterinary
[Mh] MeSH terms secundary: Analysis of Variance
Animals
Antineoplastic Combined Chemotherapy Protocols/adverse effects
Carcinoma/blood
Dogs
Erythrocyte Count
Erythrocytes/drug effects
Erythrocytes/pathology
Italy
Lymphoma/blood
Mastocytosis/blood
Retrospective Studies
[Pt] Publication type:JOURNAL ARTICLE
[Nm] Name of substance:0 (Antineoplastic Agents)
[Em] Entry month:1708
[Cu] Class update date: 170814
[Lr] Last revision date:170814
[Js] Journal subset:IM
[Da] Date of entry for processing:150626
[St] Status:MEDLINE
[do] DOI:10.1111/vco.12156

  5 / 2250 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 27646049
[Au] Autor:Barker DA; Foale RD; Holmes MA; Demetriou JL
[Ad] Address:Dick White Referrals, Station Farm, Six Mile Bottom, Newmarket CB8 0UH, UK.
[Ti] Title:Survey of UK-based veterinary surgeons' opinions on the use of surgery and chemotherapy in the treatment of canine high-grade mast cell tumour, splenic haemangiosarcoma and appendicular osteosarcoma.
[So] Source:Vet Rec;179(22):572, 2016 Dec 03.
[Is] ISSN:2042-7670
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:The objective of this study was to determine the frequency of recommendation of adjuvant chemotherapy by UK-based general veterinary practitioners (GVPs) for canine patients with high-grade mast cell tumours (HGMCTs), splenic haemangiosarcomas (SHSs) and appendicular osteosarcomas (AOSs); to determine which chemotherapeutic protocols are used by GVPs; and to evaluate reasons why chemotherapy may or may not be recommended postoperatively. An internet survey was created in 2013 using an online programme and was distributed to GVPs. Questions relating to the use of adjuvant chemotherapy for three tumours were selected. In total, 300 responses were generated. Surgery was seen as primary therapy by most GVPs for HGMCT (91 per cent) and SHS (88 per cent), but less frequently for AOS (59 per cent). Also, 90, 40 and 57 per cent of respondents recommended adjuvant chemotherapy for HGMCT, SHS and AOS, respectively. Of these, an appropriate chemotherapy protocol was not known by 25, 51 and 36 per cent of GVPs for HGMCT, SHS and AOS, respectively. From the GVPs not recommending chemotherapy, 29, 64 and 66 per cent did not believe chemotherapy to be efficacious for these tumours. The frequency of recommendation regarding postoperative chemotherapy is variable by tumour type. Reasons given why postoperative chemotherapy is not recommended also vary by tumour type.
[Mh] MeSH terms primary: Attitude of Health Personnel
Dog Diseases/drug therapy
Dog Diseases/surgery
Veterinarians/psychology
[Mh] MeSH terms secundary: Adult
Animals
Antineoplastic Combined Chemotherapy Protocols/therapeutic use
Appendiceal Neoplasms/drug therapy
Appendiceal Neoplasms/surgery
Appendiceal Neoplasms/veterinary
Chemotherapy, Adjuvant
Dogs
Hemangiosarcoma/drug therapy
Hemangiosarcoma/surgery
Hemangiosarcoma/veterinary
Humans
Mastocytosis/drug therapy
Mastocytosis/pathology
Mastocytosis/surgery
Mastocytosis/veterinary
Middle Aged
Neoplasm Grading
Osteosarcoma/drug therapy
Osteosarcoma/surgery
Osteosarcoma/veterinary
Splenic Neoplasms/drug therapy
Splenic Neoplasms/surgery
Splenic Neoplasms/veterinary
Surveys and Questionnaires
United Kingdom
Veterinarians/statistics & numerical data
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1705
[Cu] Class update date: 170817
[Lr] Last revision date:170817
[Js] Journal subset:IM
[Da] Date of entry for processing:160921
[St] Status:MEDLINE
[do] DOI:10.1136/vr.103479

  6 / 2250 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 27332907
[Au] Autor:Lorenzo ME; Carter JB; Barnes JA; Nazarian RM
[Ad] Address:From the Departments of Dermatology (M.E.L., J.B.C.), Medicine (J.A.B.), and Pathology (R.M.N.), Massachusetts General Hospital, and the Departments of Dermatology (M.E.L., J.B.C.), Medicine (J.A.B.), and Pathology (R.M.N.), Harvard Medical School - both in Boston.
[Ti] Title:CASE RECORDS of the MASSACHUSETTS GENERAL HOSPITAL. Case 19-2016. A 65-Year-Old Man with End-Stage Renal Disease and a Pruritic Rash.
[So] Source:N Engl J Med;374(25):2478-88, 2016 Jun 23.
[Is] ISSN:1533-4406
[Cp] Country of publication:United States
[La] Language:eng
[Mh] MeSH terms primary: Human T-lymphotropic virus 1/isolation & purification
Leukemia-Lymphoma, Adult T-Cell/pathology
Skin/pathology
[Mh] MeSH terms secundary: Aged
Diagnosis, Differential
Exanthema/etiology
Humans
Infection/diagnosis
Kidney Failure, Chronic/complications
Leg Injuries/complications
Leukemia-Lymphoma, Adult T-Cell/complications
Male
Mastocytosis/diagnosis
Pruritus/etiology
Sarcoma, Kaposi/diagnosis
[Pt] Publication type:CASE REPORTS; CLINICAL CONFERENCE; JOURNAL ARTICLE
[Em] Entry month:1607
[Cu] Class update date: 160623
[Lr] Last revision date:160623
[Js] Journal subset:AIM; IM
[Da] Date of entry for processing:160623
[St] Status:MEDLINE
[do] DOI:10.1056/NEJMcpc1512457

  7 / 2250 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 27178689
[Au] Autor:Grunwald MR; McDonnell MH; Induru R; Gerber JM
[Ad] Address:Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC.
[Ti] Title:Cutaneous manifestations in leukemia patients.
[So] Source:Semin Oncol;43(3):359-65, 2016 Jun.
[Is] ISSN:1532-8708
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Cutaneous complications are common in patients with leukemia. However, the cause is not always immediately clear, as there are often numerous potential etiologies. Thrombocytopenia or coagulopathy can result in ecchymoses or petechiae, whereas extramedullary (EM) involvement by leukemia can present as a rash. Leukemia can also result in skin manifestations via indirect means, including several types of paraneoplastic phenomena. Moreover, various agents routinely used to treat leukemia-most notably cytarabine (cytosine arabinoside)-can precipitate quite profound skin eruptions. Finally, infections, including fungal invasion of the skin, can be responsible for rashes, as can the vast array of antimicrobials that are administered to leukemia patients.
[Mh] MeSH terms primary: Antineoplastic Agents/adverse effects
Leukemia/pathology
Paraneoplastic Syndromes/pathology
Skin Neoplasms/pathology
[Mh] MeSH terms secundary: Adenine Nucleotides/adverse effects
Adenine Nucleotides/therapeutic use
Antineoplastic Agents/therapeutic use
Arabinonucleosides/adverse effects
Arabinonucleosides/therapeutic use
Cytarabine/adverse effects
Cytarabine/therapeutic use
Dermatomycoses/etiology
Dermatomycoses/pathology
Etoposide/adverse effects
Etoposide/therapeutic use
Humans
Leukemia/complications
Leukemia/drug therapy
Mastocytosis/pathology
Mastocytosis/secondary
Niacinamide/adverse effects
Niacinamide/analogs & derivatives
Niacinamide/therapeutic use
Paraneoplastic Syndromes/etiology
Phenylurea Compounds/adverse effects
Phenylurea Compounds/therapeutic use
Skin Diseases, Bacterial/etiology
Skin Diseases, Bacterial/pathology
Skin Neoplasms/secondary
[Pt] Publication type:JOURNAL ARTICLE; REVIEW
[Nm] Name of substance:0 (Adenine Nucleotides); 0 (Antineoplastic Agents); 0 (Arabinonucleosides); 0 (Phenylurea Compounds); 04079A1RDZ (Cytarabine); 25X51I8RD4 (Niacinamide); 6PLQ3CP4P3 (Etoposide); 762RDY0Y2H (clofarabine); 9ZOQ3TZI87 (sorafenib)
[Em] Entry month:1705
[Cu] Class update date: 170515
[Lr] Last revision date:170515
[Js] Journal subset:IM
[Da] Date of entry for processing:160515
[St] Status:MEDLINE

  8 / 2250 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy

[PMID]: 27034386
[Au] Autor:Camus MS; Priest HL; Koehler JW; Driskell EA; Rakich PM; Ilha MR; Krimer PM
[Ad] Address:Department of Pathology, University of Georgia, Athens, GA, USA mscamus@uga.edu.
[Ti] Title:Cytologic Criteria for Mast Cell Tumor Grading in Dogs With Evaluation of Clinical Outcome.
[So] Source:Vet Pathol;53(6):1117-1123, 2016 Nov.
[Is] ISSN:1544-2217
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:A 2-tiered histologic grading scheme for canine cutaneous mast cell tumors (MCTs) is based on morphologic characteristics of neoplastic cells, including karyomegaly, multinucleation, nuclear pleomorphism, and mitotic figures. Aspirates from MCTs may provide the same information more quickly, inexpensively, and less invasively. This study used these criteria to develop a cytologic grading scheme for canine MCTs to predict outcome. Three anatomic pathologists graded histologic samples from 152 canine MCTs. Three clinical pathologists evaluated aspirates from these masses using similar criteria. A cytologic grading scheme was created based on correlation with histologic grade and evaluated with a kappa statistic. Survival was evaluated with Kaplan-Meier survival curves. Cox proportional hazards regression was used to estimate hazard ratios for tumor grades and individual grading components. Simple logistic regression tested for relationships between risk factors and mortality. The cytologic grading scheme that best correlated with histology (kappa = 0.725 ± 0.085) classified a tumor as high grade if it was poorly granulated or had at least 2 of 4 findings: mitotic figures, binucleated or multinucleated cells, nuclear pleomorphism, or >50% anisokaryosis. The cytologic grading scheme had 88% sensitivity and 94% specificity relative to histologic grading. Dogs with histologic and cytologic high grade MCTs were 39 times and 25 times more likely to die within the 2-year follow-up period, respectively, than dogs with low grade MCTs. High tumor grade was associated with increased probability of additional tumors or tumor regrowth. This study concluded that cytologic grade is a useful predictor for treatment planning and prognostication.
[Mh] MeSH terms primary: Dog Diseases/pathology
Mast-Cell Sarcoma/veterinary
Skin Neoplasms/veterinary
[Mh] MeSH terms secundary: Animals
Dog Diseases/diagnosis
Dog Diseases/mortality
Dogs
Female
Male
Mast-Cell Sarcoma/diagnosis
Mast-Cell Sarcoma/mortality
Mast-Cell Sarcoma/pathology
Neoplasm Grading/veterinary
Prognosis
Skin/cytology
Skin/pathology
Skin Neoplasms/diagnosis
Skin Neoplasms/mortality
Skin Neoplasms/pathology
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1710
[Cu] Class update date: 171019
[Lr] Last revision date:171019
[Js] Journal subset:IM
[Da] Date of entry for processing:160402
[St] Status:MEDLINE

  9 / 2250 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 26811000
[Au] Autor:Xiao D; Shi Y; Fu C; Jia J; Pan Y; Jiang Y; Chen L; Liu S; Zhou W; Zhou J; Tao Y
[Ad] Address:Department of Pathology, Xiangya Hospital, Central South University, Changsha, Hunan 410078, China; Department of Pathology, School of basic medicine, Central South University, Changsha, Hunan 410078, China. Electronic address: xdsh96@21cn.com.
[Ti] Title:Decrease of TET2 expression and increase of 5-hmC levels in myeloid sarcomas.
[So] Source:Leuk Res;42:75-9, 2016 Mar.
[Is] ISSN:1873-5835
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:BACKGROUND: Myeloid sarcoma is a tumor mass that consists of myeloblasts or immature myeloid cells at an extramedullary site. Pathological diagnosis is very difficult based on morphology if systemic signs of disease are absent. The subtype of myeloid sarcoma is also minimally identifiable in the histological picture. FINDINGS: We investigated 18 paraffin-embedded myeloid sarcoma samples, and our immunohistochemical data confirmed the relevance of some key markers for the diagnosis and subclassification of myeloid sarcoma. CD34 was found as a marker in 67% of the myeloid sarcoma cases, and CD34 was positive in all immature types of myeloid sarcoma. CD68 was found in 83% of the myeloid sarcoma cases, but CD68 was most identified in the differentiated type of myeloid sarcoma. Myeloperoxidase (MPO) was positive in all myeloid sarcomas. Notably, the reactivity of MPO in the blastic subtype was much lower in myeloid sarcomas. CD117 reactivity was found in 67% of myeloid sarcomas. Ten-eleven translocation 2 (TET2) protein exhibited significant negative reactivity in 88% of the cases, and 5-methylcytosine (5-hmC) was significantly positive in the nucleus in 100% of the cases. CONCLUSIONS: Our findings indicated that an immunohistochemical panel that included MPO, CD68 and CD34 could be used for the detection of blastic, differentiated and immature types of myeloid sarcoma. Changes in novel epigenetic regulators, including the loss of TET2 and gain of 5-hmC, as characteristics of myeloid malignancies may be useful novel markers of myeloid sarcoma.
[Mh] MeSH terms primary: Biomarkers, Tumor/analysis
DNA-Binding Proteins/biosynthesis
Deoxycytidine/analogs & derivatives
Proto-Oncogene Proteins/biosynthesis
Sarcoma, Myeloid/diagnosis
[Mh] MeSH terms secundary: 5-Methylcytosine/analysis
5-Methylcytosine/biosynthesis
Adult
Antigens, CD/analysis
Antigens, CD/biosynthesis
Antigens, CD34/analysis
Antigens, CD34/biosynthesis
Antigens, Differentiation, Myelomonocytic/analysis
Antigens, Differentiation, Myelomonocytic/biosynthesis
DNA-Binding Proteins/analysis
Deoxycytidine/analysis
Deoxycytidine/biosynthesis
Female
Formaldehyde
Granulocyte Colony-Stimulating Factor/analysis
Granulocyte Colony-Stimulating Factor/biosynthesis
Humans
Immunohistochemistry
Interleukin-3/analysis
Interleukin-3/biosynthesis
Male
Middle Aged
Paraffin Embedding
Proto-Oncogene Proteins/analysis
Recombinant Fusion Proteins/analysis
Recombinant Fusion Proteins/biosynthesis
Tissue Fixation
Young Adult
[Pt] Publication type:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Name of substance:0 (5-hydroxymethyl-2'-deoxycytidine); 0 (Antigens, CD); 0 (Antigens, CD34); 0 (Antigens, Differentiation, Myelomonocytic); 0 (Biomarkers, Tumor); 0 (CD68 antigen, human); 0 (DNA-Binding Proteins); 0 (Interleukin-3); 0 (Proto-Oncogene Proteins); 0 (Recombinant Fusion Proteins); 0 (TET2 protein, human); 0 (myelopoietin); 0W860991D6 (Deoxycytidine); 143011-72-7 (Granulocyte Colony-Stimulating Factor); 1HG84L3525 (Formaldehyde); 6R795CQT4H (5-Methylcytosine)
[Em] Entry month:1607
[Cu] Class update date: 160305
[Lr] Last revision date:160305
[Js] Journal subset:IM
[Da] Date of entry for processing:160127
[St] Status:MEDLINE

  10 / 2250 MEDLINE  
              first record previous record
select
to print
Photocopy
Full text

[PMID]: 26525106
[Au] Autor:Azaña JM; Torrelo A; Matito A
[Ad] Address:Servicio de Dermatología, Complejo Hospitalario Universitario, Albacete, España. Electronic address: jmazana8@gmail.com.
[Ti] Title:Update on Mastocytosis (Part 2): Categories, Prognosis, and Treatment.
[So] Source:Actas Dermosifiliogr;107(1):15-22, 2016 Jan-Feb.
[Is] ISSN:1578-2190
[Cp] Country of publication:Spain
[La] Language:eng; spa
[Ab] Abstract:Mastocytosis is a term used to describe a heterogeneous group of disorders characterized by clonal proliferation of mast cells in different organs. The organ most often affected is the skin. The World Health Organization classifies cutaneous mastocytosis into mastocytoma, maculopapular cutaneous mastocytosis, and diffuse mastocytosis. The systemic variants in this classification are as follows: indolent systemic mastocytosis (SM), aggressive SM, SM with an associated clonal hematological non-mast cell lineage disease, mast cell leukemia, mast cell sarcoma, and extracutaneous mastocytoma. The two latest systemic variants are rare. Although the course of disease is unpredictable in children, lesions generally resolve by early adulthood. In adults, however, the disease tends to persist. The goal of treatment should be to control clinical manifestations caused by the release of mast cell mediators and, in more aggressive forms of the disease, to reduce mast cell burden.
[Mh] MeSH terms primary: Mast Cells/pathology
Mastocytosis/diagnosis
[Mh] MeSH terms secundary: Humans
Leukemia, Mast-Cell/diagnosis
Mast-Cell Sarcoma/diagnosis
Mastocytosis/classification
Mastocytosis/therapy
Mastocytosis, Cutaneous/diagnosis
Mastocytosis, Systemic/diagnosis
Prognosis
[Pt] Publication type:JOURNAL ARTICLE; REVIEW
[Em] Entry month:1709
[Cu] Class update date: 170919
[Lr] Last revision date:170919
[Js] Journal subset:IM
[Da] Date of entry for processing:151104
[St] Status:MEDLINE


page 1 of 225 go to page                         
   


Refine the search
  Database : MEDLINE Advanced form   

    Search in field  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information